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Background

Results

New insights into genetic characteristics of
leukemic cells have initiated the
development of the chimeric antigen
receptor (CAR) T-cell therapy. This type of
adoptive cell immunotherapy has been a
breakthrough in the treatment of aggressive
B-cell lymphoma and B-cell precursor acute
lymphoblastic leukemia. (NIH)

The measurement of the viral titration
showed MOI (multiplicity of infection) to be
at its highest at 48 hours. Bi-functional
CAR-T cells show increased safety for
CAR- t cell immunotherapy and enhanced
movement against cancer target antigens to
promote tumor eradication.

Previous CAR T therapies have mixed
outcomes.
The development of CD27-CARs to target
CD70 shows promising increased safety for
CAR- T cell immunotherapy.
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Methods

-Transform 27CAR plasmids in a competent
E.Coli cells
-isolate plasmid DNA from selected clones
-confirm RE Digestion
-Generate 27- CAR viral particles by
transfection
-measure viral titer
-Generate CAR- T cells

CAR-T treatment for patients with blood
tumors has shown promising outcomes.
Further study is needed. The optimization of
protocols to generate CAR-T cells has the
potential to improve the quality of cells and
thus, therapies.
The immunotherapeutic treatment of
immunocompromised patients with CAR T
cells is one of the most encouraging adoptive
cellular therapy tactics to date in the treatment
of leukemia and lymphoma. Promoting the
progression of CAR therapies will further
adopted cell therapy to cure cancers.

CD70 proteins are highly expressed in Tcell Lymphoma and Leukemia such as AML
CD27-CARs are viral particles formulated
by infecting host organisms. Particles are
functionalized by genetic and chemical
manufacturing. The construction of
lentiviral vectors constructed from plasmids
into 293T cells trough transformation,
transfection, and transduction.

CAR T cells are constructed by harvesting
mononuclear cells. These cells are usually
acquired from a patient’s own blood. T cells
are altered genetically or chemically to
express a transgene encoded with a tumorspecific CAR. The altered CAR T cells are
reinfused into the patient to multiple and
eradicate tumor cells.

We tested the efficacy of CD27- CARs to
target CD70. Through the transformation of
27CAR plasmids in a competent E-coli cell.
CD27 functional activity was assessed
through the generation of 27- CAR viral
particles by transfection. The measurement
of viral titration was examined through
Flow cytometry test. Following, the
isolation of CD70 plasmid DNA from
selected clones allows for the desired
plasmid to be confirmed through RE
(restriction enzyme) digestion. Thus,
allowing for a ligand/ receptor
communication between CD27 and CD70
and the generation of CAR T cells.

Conclusions

Developed CD27- CARs to target CD70 to
promote tumor eradicate
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Nanodrop 2000 is used to quantify and asses
the purification of DNA, RNA, protein. In
these graphs the results were low excluding
the last test with the results 258.83 (Nucleic
Acid) and 1.8 (260/280). With low results
means the CD70 protein needs to be tested
with a midiprep protocol

The protein encoded by this gene is a
cytokine that belongs to the tumor
necrosis factor (TNF) ligand family. This
cytokine is a ligand for CD27. It is a
surface antigen on activated
lymphocytes. It induces proliferation of
costimulated T cells, enhances the
generation of cytolytic T cells, and
contributes to T cell activation. This
cytokine is also reported to play a role in
regulating B-cell activation,
cytotoxic function of natural killer cells,
and immunoglobulin sythesis. (provided
by RefSeq, Jul 2008
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